Please enable JS

ARTICLES & TESTIMONIALS

Oklahoma 1115 Medicaid Waiver

Jul 08/50SN Staff/ Open Comments

January 18, 2019 The Honorable Alex Azar Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Re: SoonerCare Choice 1115(a) Demonstration Waiver Amendment Dear Secretary Azar: Thank you for the opportunity to submit comments on the SoonerCare Choice 1115(a) Demonstration Waiver Amendment. The undersigned organizations represent millions of individuals […]

READ MORE

Market Program Integrity

Jul 08/50SN Staff/ Open Comments

January 8, 2019 Submitted electronically via www.regulations.gov Honorable Alex AzarSecretaryDepartment of Health and Human Services 200 Independence Avenue, SWWashington, DC 20201 Re: Patient Protection and Affordable Care Act; Exchange Program Integrity (CMS-9922-P)Dear Secretary Azar: The 17undersigned organizations represent millions of patients and consumers facing serious, acute and chronichealth conditions across the country, including individualswho rely […]

READ MORE

Patients’ Perspectives on Febuxostat and the Importance of Education

Jul 08/50SN Staff/ Open Comments

Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement; Public Hearing Comments by the Global Healthy Living Foundation “Patients’ Perspectives on Febuxostat and the Importance of Education” January 11th , 2019 Disclosure: We have no disclosures to make regarding this comment. The Global Healthy Living Foundation […]

READ MORE

Virginia 1115 Medicaid Waiver

Jul 08/50SN Staff/ Open Comments

January 4, 2019 The Honorable Alex AzarSecretaryU.S. Department of Health and Human Services200 Independence Avenue, SWWashington, DC 20201Re: Virginia COMPASS 1115 Demonstration Extension Application –Creating Opportunities for Medicaid Participants to Achieve Self-SufficiencyDear Secretary Azar: Thank you for the opportunity to submit comments onVirginia’s Section 1115 Demonstration Extension Application. The undersigned organizations represent millions of individuals […]

READ MORE

Amgen Just Slashed Its Price of the Cholesterol-Lowering Drug Repatha. So What Does This Mean for You?

Oct 29/Lauren Gelman/ PCSK9i

You may have heard that Amgen, which manufactures the cholesterol-lowering drug evolocumab (Repatha), just announced it is lowering the list price of the drug by about 60 percent to $5,850 per year from its original list price of $14,523. The company says that the goal of the price drop is to help lower patients’ copays, […]

READ MORE